HeartSciences Inc.
HSCSWDrugs in Pipeline
21
Phase 3 Programs
7
Upcoming Catalysts
3
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
Sinerem administration
Aortic Aneurysm
Fresh frozen plasma transfusion
Blood Coagulation Disorders
Bupropion HCl ER
Acute Coronary Syndrome
triamcinolone
Lung Diseases
0.625 mg of conjugated equine estrogen
Heart Disease
Aspirin 81mg
Pulmonary Disease, Chronic Obstructive
Metoprolol Tartrate
Heart Diseases
Aerosol Interferon-Gamma
Tuberculosis
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Non-Malignant Neoplasm
6R-BH4
Renal Insufficiency, Chronic
Iocide Oral Rinse
Gingivitis
Mesenchymal Stem Cells (MSC)
Ischemic Cardiomyopathy
100 million Allogeneic Mesenchymal Human Stem Cells
Diabetes Mellitus
Inhaled Nitric Oxide
Pulmonary Embolism
Nesiritide
Congestive Heart Failure
CD34+ Hematopoietic Progenitor Cells (HSPC)
Myeloid Leukemia, Chronic
Minocycline
Hypertension
Milrinone
Valvular Stenosis
Mycophenolate Mofetil
Acute Myeloid Leukemia in Remission
Dronabinol
Sickle Cell Disease
Hydroxyurea
Sickle Cell Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sinerem administration | Phase 3 | Aortic Aneurysm | - | - |
Fresh frozen plasma transfusion | Phase 3 | Blood Coagulation Disorders | - | - |
Bupropion HCl ER | Phase 3 | Acute Coronary Syndrome | - | - |
triamcinolone | Phase 3 | Lung Diseases | - | - |
0.625 mg of conjugated equine estrogen | Phase 3 | Heart Disease | - | - |
Aspirin 81mg | Phase 3 | Pulmonary Disease, Chronic Obstructive | - | - |
Metoprolol Tartrate | Phase 3 | Heart Diseases | - | - |
Aerosol Interferon-Gamma | Phase 2 | Tuberculosis | - | - |
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10 | Phase 2 | Non-Malignant Neoplasm | - | - |
6R-BH4 | Phase 2 | Renal Insufficiency, Chronic | - | - |
Iocide Oral Rinse | Phase 2 | Gingivitis | - | - |
Mesenchymal Stem Cells (MSC) | Phase 2 | Ischemic Cardiomyopathy | - | - |
100 million Allogeneic Mesenchymal Human Stem Cells | Phase 2 | Diabetes Mellitus | - | - |
Inhaled Nitric Oxide | Phase 2 | Pulmonary Embolism | - | - |
Nesiritide | Phase 2 | Congestive Heart Failure | - | - |
CD34+ Hematopoietic Progenitor Cells (HSPC) | Phase 2 | Myeloid Leukemia, Chronic | - | - |
Minocycline | Phase 2 | Hypertension | - | - |
Milrinone | Phase 2 | Valvular Stenosis | - | - |
Mycophenolate Mofetil | Phase 2 | Acute Myeloid Leukemia in Remission | - | - |
Dronabinol | Phase 2 | Sickle Cell Disease | - | - |
Hydroxyurea | Phase 2 | Sickle Cell Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in HeartSciences Inc.'s drug pipeline?→
CatalystAlert tracks 21 drug candidates in HeartSciences Inc.'s (HSCSW) pipeline across Phase 3, Phase 2. Its lead program is Sinerem administration (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is HeartSciences Inc.'s next FDA catalyst?→
HeartSciences Inc.'s (HSCSW) next tracked catalyst is a Phase 3 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HSCSW biotech catalysts?→
Add HSCSW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow HeartSciences Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.